Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer

Advancing chimeric antigen receptor (CAR)-engineered adoptive T cells for the treatment of solid cancers is a major focus in the field of immunotherapy, given impressive recent clinical responses in hematological malignancies. Prostate cancer may be amenable to T cell-based immunotherapy since sever...

Descripción completa

Detalles Bibliográficos
Autores principales: Priceman, Saul J., Gerdts, Ethan A., Tilakawardane, Dileshni, Kennewick, Kelly T., Murad, John P., Park, Anthony K., Jeang, Brook, Yamaguchi, Yukiko, Yang, Xin, Urak, Ryan, Weng, Lihong, Chang, Wen-Chung, Wright, Sarah, Pal, Sumanta, Reiter, Robert E., Wu, Anna M., Brown, Christine E., Forman, Stephen J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5749625/
https://www.ncbi.nlm.nih.gov/pubmed/29308300
http://dx.doi.org/10.1080/2162402X.2017.1380764

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5749625/
https://www.ncbi.nlm.nih.gov/pubmed/29308300
http://dx.doi.org/10.1080/2162402X.2017.1380764

Ejemplares similares